A cell permeable peptide inhibitor of NFAT inhibits macrophage cytokine expression and ameliorates experimental colitis by Elloumi, HZ et al.
A Cell Permeable Peptide Inhibitor of NFAT Inhibits
Macrophage Cytokine Expression and Ameliorates
Experimental Colitis
Houda Z. Elloumi1., Nitsan Maharshak1., Kavitha N. Rao2., Taku Kobayashi1, Hyungjin S. Ryu1,
Marcus Mu¨hlbauer1, Fengling Li1, Christian Jobin1, Scott E. Plevy1*
1Center for Gastrointestinal Biology and Diseases, Departments of Medicine and Department of Microbiology and Immunology, University of North Carolina School of
Medicine, Chapel Hill, North Carolina, United States of America, 2Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania,
United States of America
Abstract
Nuclear factor of activated T cells (NFAT) plays a critical role in the development and function of immune and non-immune
cells. Although NFAT is a central transcriptional regulator of T cell cytokines, its role in macrophage specific gene expression
is less defined. Previous work from our group demonstrated that NFAT regulates Il12b gene expression in macrophages.
Here, we further investigate NFAT function in murine macrophages and determined the effects of a cell permeable NFAT
inhibitor peptide 11R-VIVIT on experimental colitis in mice. Treatment of bone marrow derived macrophages (BMDMs) with
tacrolimus or 11R-VIVIT significantly inhibited LPS and LPS plus IFN-c induced IL-12 p40 mRNA and protein expression. IL-12
p70 and IL-23 secretion were also decreased. NFAT nuclear translocation and binding to the IL-12 p40 promoter was
reduced by NFAT inhibition. Experiments in BMDMs from IL-10 deficient (Il102/2) mice demonstrate that inhibition of IL-12
expression by 11R-VIVIT was independent of IL-10 expression. To test its therapeutic potential, 11R-VIVIT was administered
systemically to Il102/2 mice with piroxicam-induced colitis. 11R-VIVIT treated mice demonstrated significant improvement
in colitis compared to mice treated with an inactive peptide. Moreover, decreased spontaneous secretion of IL-12 p40 and
TNF in supernatants from colon explant cultures was demonstrated. In summary, NFAT, widely recognized for its role in T
cell biology, also regulates important innate inflammatory pathways in macrophages. Selective blocking of NFAT via a cell
permeable inhibitory peptide is a promising therapeutic strategy for the treatment of inflammatory bowel diseases.
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Introduction
Macrophages perform numerous critical functions during
immune responses such as phagocytosis, microbial killing, antigen
presentation to T cells, and production of inflammatory mediators.
Microbial stimulation of macrophages through toll-like receptors
(TLRs) leads to a cascade of signaling events culminating in the
production of various inflammatory cytokines including IL-12, IL-
23 and TNF; and antimicrobial mediators such as free oxygen
radicals, nitric oxide (NO) and proteases. Expression of these
mediators needs to be tightly regulated, as failure could contribute
to the pathogenesis of chronic inflammation in diseases including
rheumatoid arthritis, multiple sclerosis and inflammatory bowel
diseases (IBD) [1].
The IL-12 family of cytokines has been implicated in the
pathogenesis of numerous chronic inflammatory disorders
[2,3,4,5]. IL-12 and IL-23 are heterodimeric cytokines composed
of a common p40 subunit in addition to p35 and p19 subunits,
respectively. IL-12 is involved in the development of a T-helper-1
(Th1) response [6,7]. IL-23 is involved in the maintenance of Th17
cells [8]. IL-12 p40 is expressed specifically in macrophages and
dendritic cells [9] and is highly induced by microbial constituents
such as LPS, CpG rich bacterial DNA, lipoproteins and T-cell
dependent cognate interactions [7]. Detailed molecular charac-
terization of IL-12 p40 (Il12b) promoter activation by microbes
and cytokines has described complex regulation through numer-
ous protein-DNA and protein-protein interactions [10,11,12]. Our
group described a novel composite element in the Il12b promoter
that interacts with members of the nuclear factor of activated T
cells (NFAT) and the interferon regulatory factor (IRF) families of
transcription factors [10]. This element is involved in the
synergistic induction of Il12b promoter activity by bacterial
products and interferon-gamma (IFN-c).
The NFAT family of transcription factors plays a key role in
cytokine gene expression in T cells. Five NFAT family members
have been identified, four of which are calcium-regulated and
require the calcium/calmodulin-dependent phosphatase, calci-
neurin, for their nuclear localization. The role of NFAT in
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immune responses has been best characterized in T cells. Upon T
cell activation by antigen, intracellular calcium levels increase and
calcineurin is consequently activated. This serine/threonine
phosphatase activates cytosolic NFAT through its dephosphory-
lation which results in activated NFAT translocation to the nucleus
and in inflammatory cytokines production. NFAT has also been
described to mediate gene expression in other cells of the immune
system and other organ systems [13]. However, less is known
about NFAT function in other cells of the immune system,
specifically macrophages, although its role in related cell types
such as dendritic cells and osteoclasts is under intensive
investigation over the past few years [14,15,16,17]. Moreover,
calcineurin inhibitors have been reported to inhibit IL-12 p40
expression in human monocytic cells [18].
Calcineurin inhibitors, such as tacrolimus and cyclosporine
(CsA), bind to specific binding proteins (FK506-binding proteins
and cyclophilins, respectively) and these complexes attach to
calcineurin and prevent its dephosphorylation-induced NFAT
activation. These agents revolutionized transplantation medicine
through prevention of graft rejection and consequent dramatic
improvement in patient survival [19,20,21]. Their use has been
extended to chronic inflammatory diseases such as the inflamma-
tory bowel diseases and psoriasis [22].
In contrast to the calcineurin inhibitors, a short peptide, VIVIT,
inhibits NFAT activation through interaction with the calcineurin
binding site for NFAT and thus prevents nuclear translocation
without affecting calcineurin phosphatase activity [23]. Protein
transduction domains (PTD), such as polyarginines and the HIV
Tat peptide, have been utilized to facilitate the delivery of various
cargo molecules into a variety of cells. PTD-mediated VIVIT
delivery has demonstrated blockade of NFAT and therapeutic
efficacy in various murine inflammatory disease models [24,25]. In
this study, we used the cell permeable peptide 11R-VIVIT to
characterize the role of NFAT in macrophage-specific gene
expression. VIVIT attenuated LPS or LPS plus IFN-c induced IL-
12 p40 mRNA and protein expression in bone marrow derived
macrophages (BMDMs) and reduced DNA binding of NFAT to a
composite NFAT–interferon stimulated response element (ISRE)
on the Il12b promoter. In addition, VIVIT inhibited the
production of NO and the secretion of IL-12 p70, IL-23, and
TNF suggesting a global role for NFAT in inflammatory gene
expression in macrophages. Furthermore, as an in vivo correlate,
11R-VIVIT ameliorated active colitis in piroxicam-treated IL-10
deficient (Il102/2) mice. Histologic improvement correlated with
reduced spontaneous secretion of colonic inflammatory cytokines
including IL-12 p40.
Materials and Methods
Mice
Seven to ten weeks old C57/BL6 and Il102/2 mice on a C57/
BL6 background were purchased from the Jackson Laboratories.
All animals were housed in specific pathogen free conditions (SPF)
in accordance with guidelines from the American Association for
Laboratory Animal Care and Research. Il102/2;NF-kBEGFP
reporter mice (129/SvEv/C57BL6 background) were generated
by Christian Jobin as previously described [26]. The Institutional
Animal Care and Use Committee of the University of North
Carolina approved all animal protocols (Permit Number: 06-239). To
study the effects of the cell permeable inhibitor peptide 11R-
VIVIT, the non-steroidal anti-inflammatory piroxicam (200 ppm)
was added to the mice diet for 14 days as a well validated
approach to accelerate the development of colitis in Il102/2 mice
[27]. After the establishment of colitis and withdrawal of
piroxicam from the diet, sex and age- matched Il102/2 mice
were randomized to receive 11R-VIVIT or the control peptide
11R-VEET were delivered by intra-peritoneal injection every
other day for 2 weeks. At the end of treatment period, the mice
were euthanized and the colons were immediately removed.
Reagents
Lipopolysaccharide (LPS) from Salmonella enteritidis was pur-
chased from Sigma (St. Louis, MO). Tacrolimus was purchased
from Alexis Biochemicals (San Diego, CA). Recombinant murine
IFN-c was purchased from R&D Systems. M-CSF was obtained
from Peprotech Inc (Rocky Hill, NJ). Antibodies to NFATc1 (K18)
and IRF8 (H-70) were purchased from Santa Cruz Biotechnology
(Santa Cruz, CA).
Peptide synthesis
11R-VIVIT (RRRRRRRRRRRGGGMAGPHPVIVITGPH-
EE) and 11R-VEET (RRRRRRRRRRRGGGMAGPPHIVEE-
TGPHVI) peptides were synthesized and HPLC-purified (.95%)
by GenScript (Piscataway, NJ) and at the peptide synthesis
facilities of the University of North Carolina and the University of
Pittsburgh or purchased through EMD Bioscience. 11R-VIVIT
from EMD Bioscience will be referred to as VIVITEMD since this
VIVIT was active at significantly lower concentrations compared
to the VIVIT from GenScript.
Bone marrow macrophage culture
Bone marrow derived macrophages (BMDMs) were prepared as
described [28].
EGFP Imaging
Epifluorescence microscopy was used to detect EGFP in bone
marrow derived macrophages derived from cis-NF-kBEGFP mice.
EGFP expression was imaged using an Olympus IX70 (Olympus,
Melville, NY) fitted with EGFP-specific filters (XF116-2; Omega
Optical). Images were captured using a digital SPOTM camera
(Diagnostic Instruments, McHenry, IL). Identical exposure times
were used for each data point within an individual experiment.
EGFP positive cells per high power field were counted and were
expressed as a percentage of total number of cells.
Electrophoretic mobility shift assays
Nuclear extracts from BMDMs were prepared using the NE-
PER kit from Pierce Biotechnology, following the manufacturer’s
instructions. The sequence of the EMSA probe spanning the
NFAT/IRF8 site of the IL-12 p40 promoter is 59-gatcTCA-
GTTTCTACTTTGGGTTTCCATCAGAAAGT. EMSAs were
performed as described previously [10].
Real-time RT-PCR
Total RNA was extracted using either the TRIZOL reagent
(Invitrogen, Carlsbad, CA) or the RNeasy mini kit (Qiagen,
Valencia, CA). Real-time RT-PCR was performed as described
previously [29] to detect Il12b and Nos2 mRNA.
Cytokine ELISA
Murine IL-12 p40, IL-12 p70, IL-10, interferon-c and TNF
immunoassay kits (R & D Systems, Minneapolis, MN) were used
according to manufacturers’ instructions.
Nitrite Determination
Nitrite concentration was assayed by a standard Greiss Reaction
adapted to a microplate system, as described previously [28].
NFAT Inhibition Reduces Inflammation
PLoS ONE | www.plosone.org 2 March 2012 | Volume 7 | Issue 3 | e34172
T cell purification and activation
Splenic CD4+ T cells were purified from WT mice using CD4
(L3T4) Microbeads (Miltenyi Biotec) then stimulated with plate
bound anti-CD3 (5 mg/ml) and anti-CD28 (2 mg/ml) (eBioscience)
and exposed to various concentrations of 11R-VIVITEMD or
VEET. Cells were harvested after 4 hours for mRNA and
supernatants were collected after 48 hours for ELISA.
Colonic tissue explant culture and histology
Colonic explant cultures were performed as described previ-
ously [29]. Fixed and paraffin embedded colonic sections were
stained with hematoxylin and eosin (H&E). Sections were then
visualized by light microscopy and histologic scores determined by
three independent experienced investigators blinded to treatment
group. Colitis severity index was determined based on standard
criteria for inflammation, edema, hyperplasia, and atrophy as
previously described [30].
Statistical analysis
All results are expressed as mean 6 SEM/SD. Using GraphPad
Prism software, Mann Whitney and unpaired student’s t test were
used to assess statistical significance where appropriate.
Results
NFAT regulates Il12b gene expression
We have previously demonstrated a composite NFAT DNA
binding site/interferon stimulated response element in the Il12b
promoter [10]. To investigate the functional role of NFAT in Il12b
expression, we utilized the well characterized and clinically relevant
NFAT inhibitor tacrolimus. In bone marrow derived macrophages
(BMDMs) stimulated with LPS alone or LPS plus IFN-c, IL-12 p40
protein secretion was inhibited by tacrolimus in a dose dependent
manner (Figure 1A). Il12b mRNA also demonstrated similar dose-
dependent inhibition by tacrolimus (Figure 1B).
Tacrolimus inhibits calcineurin activation and may have effects
on other important signal transduction pathways such as NF-kB
[18,31]. To validate these findings and importantly, to demon-
strate specificity for NFAT activation, we utilized the cell
permeable peptide 11R-VIVIT. In LPS and LPS plus IFN-c
stimulated BMDMs, 11R-VIVIT dose dependently attenuated IL-
12 p40 protein secretion (Figure 2A) and Il12b mRNA expression
(Figure 2B). The inactive control peptide 11R-VEET did not
inhibit IL-12 p40 production in LPS or LPS and IFN-c activated
BMDMs (Figure 2A).
NFAT regulates the inflammatory cytokines IL-12 p70, IL-
23 and TNF
IL-12 p40 heterodimerizes with the IL-12 p35 and IL-23 p19
subunits, respectively, to form the biologically active cytokines IL-
12 p70 and IL-23. In BMDMs stimulated with LPS plus IFN-c,
11R-VIVIT inhibited IL-12 p70 (Figure 3A) and IL-23
(Figure 3B) in a dose-dependent manner, while the control
11R-VEET peptide had no effect. Regulation of TNF by NFAT
in T cells, B cells and myelomonocytes has been described in
previous studies [32,33,34]. 11R-VIVIT suppressed the induction
of TNF by LPS plus IFN-c, while the control 11R-VEET did not
(Figure 3C).
11R-VIVIT inhibits NFAT DNA binding to the murine Il12b
promoter
We next analyzed DNA binding of NFAT to the NFAT/IRF8
site in the Il12b promoter by EMSA using nuclear extracts
obtained from murine BMDMs. Activation of BMDMs with LPS
and IFN-c induced DNA-protein complex formation on an
oligonucleotide probe containing the NFAT/IRF8 element,
spanning the region from 288 to 254 (with respect to the
transcription start site) of the murine Il12b promoter (Figure 4,
lane 2). The presence of NFAT and IRF8 in this complex was
confirmed by supershift using anti-NFAT and anti-IRF8 antibod-
ies. Anti-NFAT antibody generated a supershift whereas anti-
IRF8 antibody abrogated complex formation, as shown previously
[10]. Treatment with 11R-VIVIT reduced DNA-protein complex
formation in LPS and IFN-c stimulated BMDMs (Figure 4,
compare lanes 2 and 5). Supershifted bands showed reduced
amounts of NFAT (Figure 4, compare lanes 3 and 6) and IRF8
(Figure 4, compare lanes 4 and 7). Furthermore, treatment of cells
with the control 11R-VEET peptide did not affect DNA-protein
complex formation (Figure 4, lanes 2–4). The above results
demonstrate that the VIVIT peptide prevented nuclear translo-
cation of NFAT leading to reduced DNA-protein complex
formation in vitro. In addition, these results suggest that VIVIT
Figure 1. Tacrolimus inhibits IL-12 p40 protein and mRNA
expression. (A) Murine bone marrow-derived macrophages (BMDMs)
were pretreated with the indicated concentrations of tacrolimus for 1 h.
Cells were then either left untreated (NS) or stimulated with LPS
(100 ng/ml) or LPS and IFN-c (10 ng/ml) for 24 h. IL-12 p40 protein
secretion was assayed from supernatants by ELISA. (B) BMDMs were
incubated with the indicated concentrations of tacrolimus for 1 h
followed by 1 h treatment with IFN-c (10 ng/ml, where indicated) prior
to LPS (100 ng/ml) stimulation for 4 h or left untreated (NS). Cells were
harvested and total RNA was assayed for Il12b mRNA levels by real-time
RT-PCR. Each result represents the mean 6 standard error (SD) for
duplicate assays from three independent experiments. * p,0.05.
doi:10.1371/journal.pone.0034172.g001
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inhibits IRF8 DNA binding as well, consistent with our previous
model where NFAT binding recruits IRF8 to the Il12b promoter
[10].
NFAT is involved in inducible nitric oxide synthase (Nos2)
expression
We previously reported that IRF8 and IRF1 are essential for
induction of the Nos2 gene in macrophages [35]. Furthermore,
Nos2 regulation by calcineurin was also demonstrated in intestinal
epithelial and macrophage cell lines [36,37]. Based on these data,
we postulated that the interaction between IRF8 and NFAT
demonstrated on the Il12b promoter is likely to be relevant for
expression of other genes. Through a database search, we
identified a putative composite ISRE-NFAT binding site in the
murine Nos2 promoter [38] (Figure 5A). DNA binding of NFAT
and IRF8 was next analyzed by EMSA using nuclear extract from
BMDMs stimulated with LPS and IFN-c. Supershift experiments
demonstrate the presence of NFAT and IRF8 in the same protein
complex bound to a probe spanning the ISRE binding element
(Figure 5A, lanes 4 and 7). To examine the role of NFAT in Nos2
expression, we assayed nitric oxide production (measured as nitrite
accumulation) by BMDMs treated with 11R-VIVIT. Inhibition of
NFAT attenuated nitric oxide production (Figure 5B) and Nos2
mRNA expression (Figure 5C) in a dose dependent manner. Thus,
these results suggest that NFAT mediates the expression of Nos2
and nitric oxide production in BMDMs.
Inhibition of IL-12 p40 by VIVIT is independent of IL-10
IL-10 is an anti-inflammatory cytokine which inhibits macro-
phage activation and the pro-inflammatory response [39].
Importantly, IL-10 inhibits IL-12 p40 transcription [40]. There-
fore, we determined whether inhibition of IL-12 p40 by VIVIT
was mediated by induction of IL-10. IL-10 levels were evaluated in
cell free supernatants of BMDMs treated with either 11R-VIVIT
or control 11R-VEET (Figure 6A). Inhibition of NFAT did not
significantly affect IL-10 in LPS or LPS plus IFN-c-treated
BMDMs. Furthermore, compared to the control peptide, 11R-
Figure 2. 11R-VIVIT inhibits IL-12 p40 protein and mRNA
expression. (A) Murine bone marrow-derived macrophages (BMDMs)
were either untreated or pretreated with the indicated concentrations
of 11R-VIVIT or the control peptide 11R-VEET for 1 h followed by LPS
(100 ng/ml) alone or together with IFN-c (10 ng/ml) for 24 h. IL-12 p40
protein secretion was assayed from supernatants by ELISA. (B) BMDMs
were either untreated or pretreated with the indicated concentrations
of 11R-VIVIT for 1 h followed by 1 h treatment with IFN-c (10 ng/ml)
prior to LPS (100 ng/ml) treatment for 4 h. Cells were harvested and
total RNA was assayed for Il12b mRNA levels by real-time RT-PCR.
Results were normalized with the respect to the levels of b-actin mRNA,
and represent the mean 6 SE for duplicate assays from three
independent experiments. * p,0.05, ** p,0.01.
doi:10.1371/journal.pone.0034172.g002
Figure 3. 11R-VIVIT inhibits pro-inflammatory cytokine expres-
sion in murine macrophages. BMDMs from WT mice were either
untreated or pretreated with the indicated concentrations of 11R-VIVIT
or 11R-VEET for 1 h followed by LPS (100 ng/ml) and IFN-c (10 ng/ml)
for 24 h. IL-12 p70 (A), IL-23 (B) and TNF (C) protein secretion were
assayed from supernatants by ELISA. Each result represents mean 6 SE
of duplicate assays from three independent experiments. * p,0.05.
doi:10.1371/journal.pone.0034172.g003
NFAT Inhibition Reduces Inflammation
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VIVIT inhibits IL-12 p40 in BMDMs derived from Il102/2 mice
in a dose dependent manner (Figure 6B), substantiating that
VIVIT inhibits IL-12 p40 expression through IL-10 independent
pathways.
Inhibition of IL-12 p40 is not induced through disruption
of TLR4 signaling
To verify that 11R-VIVIT does not inhibit LPS induced IL-12
p40 production through disruption of the LPS-TLR4 signaling
pathway, we studied the effects of 11R-VIVITEMD on LPS
stimulated BMDMs isolated from Il102/2;NF-kBEGFP mice. The
percentage of GFP positive cells was similar for LPS activated
BMDMs (8.560.97%) exposed to VIVIT (9.262.2%) and VEET
(960.96%), all significantly higher (P,0.05) compared to cells that
were exposed to PBS alone (1.7960.1%), suggesting that 11R-
VIVIT does not inhibit LPS induced NF-kB activation (Figure S1,
representative images).
Administration of 11R-VIVIT ameliorates experimental
colitis
We postulated that blocking the calcineurin/NFAT pathway
with 11R-VIVIT could ameliorate IL-12/23 mediated experi-
mental colitis. We examined the effects of 11R-VIVIT adminis-
tration on the course of colitis in piroxicam treated Il102/2 mice,
a commonly used murine IBD model characterized by increased
colonic Il12b expression [29]. The cyclooxygenase 1 and 2
inhibitor, piroxicam (200 ppm), was added to the diet of 5 weeks
old mice for 14 days as a validated approach to accelerate the
development and increase the penetrance of colitis in Il102/2
mice [27].
High doses of 11R-VIVIT (2 and 10 mg/kg) decreased colitis
scores significantly (Figure 7A) compared to an inactive cell
permeable control peptide (11R-VEET). However, high doses of
VIVIT may also inhibit T regulatory cell populations [41] and
consequently increase inflammation. Consequently we repeated
the experiment (Figure 7B) and demonstrate amelioration of colitis
at doses as low as 0.5 mg/kg. To confirm the therapeutic effects of
VIVIT at low dosage, a large cohort of mice (n = 21) were treated
with 1 mg/kg of 11R-VIVIT or 11R-VEET every other day for
two weeks following 14 days of piroxicam administration.
Administration of 11R-VIVIT demonstrated therapeutic efficacy
as measured by increases in body weight and gross colonic
appearance. Colons from VIVIT treated mice showed formed
stool pellets and decreased wall thickening (Figure S2). Consistent
with macroscopic observations, histological examination showed
reduced numbers of infiltrating cells within the submucosa and
lamina propria in the VIVIT treated mice compared to VEET
treated ones (Figure S2B). Epithelial damage and hyperplasia were
significantly reduced in VIVIT treated mice (Figure S2B).
Furthermore, a significant decrease in histological scores in mice
receiving 11R-VIVIT compared to those receiving 11R-VEET
was observed in 3 independent experiments (Figure 7C).
Treatment with 11R-VIVIT reduces colonic secretion of
pro-inflammatory cytokines
We next investigated whether the expression of colonic pro-
inflammatory cytokines correlated with histologic improvement in
11R-VIVIT treated Il102/2 mice. 11R-VIVIT treatment in vivo
significantly down-regulated the production of IL-12 p40
(19.662.65 pg/ml versus 51.87617.43 pg/ml in controls;
p = 0.048) and IFN-c levels (5336182 pg/ml vs 19566650 pg/
ml; p = 0.046); while TNF levels were marginally decreased
(Figure 8) in colonic explant cultures. As IFN-c is the signature
Th1 cytokine downstream of IL-12 signaling, decreased colonic
IFN-c may be a consequence of lower IL-12 levels in vivo, but
VIVIT may also have direct effects on inflammatory T cells, as
previously demonstrated [23]. Indeed, 11R-VIVIT directly
inhibited release of IFN-c from anti-CD3/CD28 activated T cells
in culture (Figure S3).
Discussion
In this study, we demonstrate that intracellular delivery of 11R-
VIVIT inhibited expression and secretion of inflammatory
cytokines in macrophages and ameliorated active colitis in
piroxicam treated Il102/2 mice. Thus, modulation of NFAT
activity by this cell permeable peptide could be an effective
therapeutic strategy in inflammatory bowel disease.
The NFAT family is a complex family of transcription factors
with five proteins, each member having different alternatively
spliced isoforms. NFAT is important for the development and
function of numerous major organ systems including the nervous
system, heart, blood vessels, kidney, bone and muscle [13]. NFAT
transcription factors play an important role in regulating immune/
inflammatory signaling, with the best described effects on T cell
activation and phenotype. NFAT also regulates gene expression in
other immune cells such as B cells [42], mast cells [43], eosinophils
Figure 4. 11R-VIVIT reduces DNA binding to the NFAT/IRF8 site
in the murine IL-12 p40 promoter. BMDMs were either untreated
(lane 1) or pretreated with the indicated concentrations of 11R-VEET
(lanes 2–4) or 11R-VIVIT (lanes 5–7) for 1 h. Cells were then treated for
1 h with IFN-c (10 ng/ml) prior to LPS (100 ng/ml) stimulation for 4 h.
Cells were harvested and nuclear extracts were prepared for EMSA. 32P
labeled oligonucleotide probe spanning the NFAT/IRF8 site of the IL-12
p40 promoter [10] was incubated with 10 mg of nuclear extracts on ice
for 30 min prior to electrophoresis. For supershift assays (lanes 3,4 and
6,7), 10 mg nuclear extract were incubated with 3 mg of anti-NFAT c1
(lanes 3 and 6) or anti-IRF8 (lanes 4 and 7) antibodies for 30 min on ice
prior to addition of the 32P labeled probe and 30 min incubation on ice
followed by electrophoresis. The arrows represent DNA-protein
complexes formed before and after incubation with the indicated
antibodies. The above result is representative of five independent
experiments.
doi:10.1371/journal.pone.0034172.g004
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[44], basophils [45] and NK cells [46]. In dendritic cells, LPS
stimulation resulted in Ca2+ influx and NFAT activation that
regulated their life cycle [15]. NFAT proteins are involved in the
differentiation of monocyte/macrophage lineage cells into osteo-
clasts [47]. However, knowledge of NFAT function specifically in
macrophages is limited. Macrophages express NFAT family
members [10,47] and in our previous study, we demonstrated
the requirement for NFATc1 and c2 in Il12b gene expression in a
murine macrophage cell line [10]. Ca2+/calcineurin signaling has
been implicated in macrophage biology, with conflicting results
reported. Conboy and colleagues showed that Ca2+/calcineurin
signaling inhibited macrophage cytokine production [48]. How-
ever, a later study reported that calcineurin signaling induced Nos2
expression and NO secretion in murine macrophages [49].
Moreover, the African swine fever virus protein, A238L has been
shown to inhibit inflammatory gene expression in infected
macrophages by binding to calcineurin and inhibiting NFAT-
dependent gene expression [50]. Furthermore, in a study by
Jeffrey et al. [51], macrophages deficient for the dual specificity
phosphatase- PAC-1, displayed decreased activation of NFAT and
diminished expression of pro-inflammatory mediators.
Here, we show that NFAT is important for pro-inflammatory
gene expression by murine macrophages using the selective
inhibitory peptide VIVIT. NFAT regulates the expression of the
Figure 5. NFAT binds to Nos2 promoter and its selective inhibition abrogates nitric oxide secretion in macrophages. (A) Nuclear
extracts were prepared from BMDMs stimulated with LPS (lane 1) or LPS and IFN-c (lanes 2–7). Extracts were either incubated with a labeled probe
NFAT/ISRE (element from region II of the promoter scheme), a competitor ISRE oligonucleotide, or with the indicated antibodies. DNA-protein
complexes (indicated by arrow) were separated by electrophoresis. EMSA revealed binding of both IRF8 and NFATc1 to the same Nos2 promoter
element. (B) BMDMs from WT mice were either untreated or pretreated with the indicated concentrations of 11R-VIVIT or the control peptide for 1 h
followed by LPS (100 ng/ml) and IFN-c (10 ng/ml) for 24 h. Nitric oxide secretion was assayed from supernatants by Greiss reaction. Experiments
were performed in duplicate and repeated three times (mean 6 SEM). (C) BMDMs were either untreated or pretreated with the indicated
concentrations of 11R-VIVIT for 1 h followed by 1 h treatment with LPS alone or IFN-c (10 ng/ml) prior to LPS (100 ng/ml) treatment for 4 h. Cells
were harvested and total RNA was assayed for Nos2 mRNA levels by real-time RT PCR. Data is representative of three independent experiments. *
p,0.05.
doi:10.1371/journal.pone.0034172.g005
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Il12b gene, thereby controlling the levels of the bioactive
heterodimers of IL-12 p70 and IL-23. We also show that NFAT
regulates TNF and Nos2 expression in BMDMs. Although an
NFAT binding site has been reported within the Tnf gene in T
cells [52,53], the importance of this element is far less established
in macrophages and thus, it is unclear whether VIVIT-dependent
reduction in TNF secretion is mediated through direct inhibition
of NFAT recruitment to the Tnf gene or through indirect effects
(eg, post-transcriptional regulation) in cells and/or a general
reduction in inflammation in vivo. Importantly, we show that
VIVIT-dependent inhibition of LPS-induced inflammatory medi-
ator secretion is not through inhibition of the canonical TLR4
signaling pathway, as VIVIT does not abrogate NF-kB activation
in BMDMs. Thus, NFAT, functioning as a complex with IRF
family members or other interacting partners has a general yet
underappreciated role in programming macrophage gene expres-
sion. In support of our findings, it has been reported that VIVIT
effectively inhibited LPS induced secretion of TNF and MCP-1 in
murine microglia cultures [54].
Figure 6. Inhibition of IL-12 p40 by 11R-VIVIT is independent
of IL-10. (A) Murine BMDMs were either untreated or pretreated with
the indicated concentrations of 11R-VIVIT (white bars) or 11R-VEET
(black bars) for 1 h followed by LPS (100 ng/ml) alone or together with
IFN-c (10 ng/ml) for 24 h. IL-10 protein secretion was assayed from
supernatants by ELISA. (B) BMDMs from Il102/2 mice were either
untreated or pretreated with the indicated concentrations of 11R-VIVIT
or 11R-VEET for 1 h followed by LPS (100 ng/ml) and LPS plus IFN-c
(10 ng/ml) for 24 h. IL-12 p40 protein secretion was assayed from
supernatants by ELISA. Results represent the mean 6 SD for duplicate
assays from three independent experiments. * p,0.05, ** p,0.01.
doi:10.1371/journal.pone.0034172.g006
Figure 7. Therapeutic effect of VIVIT on piroxicam induced
colitis in Il102/2 mice. Piroxicam fed IL-10 deficient mice were
injected with the indicated doses of either VIVIT or VEET peptides (6–7
mice per group) every other day for two weeks. Colons were then
harvested and colitis scores were determined as described in materials
and methods. (A–B) An inverse dose response of VIVIT therapy was
noted, with a higher mortality rate at 10 mg/kg (A) and amelioration of
colitis detected at as low as 0.5 mg/kg following one week of piroxicam
diet (B). (C) 1 mg/kg of either peptide was then administered to a
group of 21 piroxicam fed Il102/2 mice. The scores for histological
damage during piroxicam-induced colitis were significantly higher in
VEET treated mice compared to those receiving VIVIT peptide in all
reported experiments. Data shown are mean 6 SEM.
doi:10.1371/journal.pone.0034172.g007
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Moreover, VIVIT administration in vivo ameliorates colitis in
Il102/2 mice and histologic improvement correlated with
decreased colonic IL-12 p40 secretion. Although, VIVIT at
10 mg/kg was effective in amelioration of colitis, we show that
doses as low as 0.5 mg/kg were effective. These data suggest that
VIVIT treatment contributed to the amelioration of piroxicam
induced colitis in Il102/2 mice, in part by decreasing pro-
inflammatory cytokine release by macrophages. However, NFAT
has an important role in regulation of T cells, and since Il102/2
colitis model is driven by the innate and adaptive immune system,
we cannot exclude inhibitory effects of VIVIT on T cells as an
additional mechanism for amelioration of colitis. Indeed, NFAT
proteins are involved in the induction and regulation of Th1, Th2
and Th17 responses. In fact, NFATc1 and c2 deficient mice
display impaired Th1 and Th2 response [55,56], and NFATc2
deficiency has been reported to suppress colitis induced by
oxazolone administration [57]. Furthermore, sustained NFATc1
signaling has been shown to promote a Th1-like pattern of gene
expression in murine CD4+ T cells [58]. Accordingly, we found
that colonic IFN-c levels were reduced in Il10-/- mice exposed to
11R-VIVIT in vivo. As IFN-c is the signature IL-12 induced Th1
cytokine, this phenomenon may be a consequence of decreased
IL-12 in vivo, but VIVIT may also have direct effects on
inflammatory T cells, as previously demonstrated [23] and
confirmed in this study (Figure S3). Moreover, NFAT was shown
to be important for the induction of Th17 signature cytokines , IL-
17, IL-21 and IL-22 [59]. NFAT2 was also reported to play vital
role in FoxP3 transcription and hence T regulatory cell expansion
[41,60,61]. Interestingly, exposing mice to higher doses of VIVIT
in vivo may not be as effective in ameliorating colitis as lower
concentrations, as is suggested by our experimental results
(Figure 7), due to inhibition of T regulatory cell activation or
expansion.
Additional NFAT-driven mechanisms that may contribute to
the decrease in chronic intestinal inflammation may include effects
on dendritic cells. Zanoni et al [15] have shown that exposure of
dendritic cells to LPS results in apoptosis which is dependent on
NFAT. Blocking of this pathway may result in the maintenance of
dendritic cells with regulatory properties. Intestinal dendritic cells
have a prominent role in tolerance induction towards bacterial
antigens. In addition Jennings et al [62] have shown that
calcineurin inhibition leads to decreased responsiveness (tolerance)
to LPS in macrophages and dendritic cells. This finding may
suggest an alternative mechanism of immune response down-
regulation towards enteric bacteria and bacterial products.
There are now numerous examples of PTD-containing peptides
having significant effects in preclinical models of inflammatory
disease [63,64]. Although the mechanisms through which PTDs
deliver their cargo intracellularly are not completely delineated,
cells specialized to sample the environment such as macrophages
and dendritic cells may be preferential targets for PTDs (as
opposed to small molecules).
The immunosuppressive agents CsA and tacrolimus inhibit the
phosphatase activity of calcineurin, thus preventing nuclear
localization of NFAT [65]. However, the use of CsA and
tacrolimus in chronic inflammatory disorders is limited by
toxicities, including chronic nephro- and neurotoxicity among
other significant side effects [66,67]. These agents also inhibit
other pathways downstream of calcineurin which could lead to
undesired effects [66,67]. Unlike tacrolimus and CsA, VIVIT will
not affect calcineurin activity, which speculatively poses safety
advantages in human disease. Other non-NFAT related mecha-
nisms have been described for calcineurin inhibitors. Relevant to
this study, in a human promonocytic cell-line, calcineurin
Figure 8. VIVIT treatment reduces spontaneous secretion of
colonic inflammatory cytokines. Explants from colons of VIVIT
(n = 12 for A, B; n = 7 for C) and VEET (n = 9 for A, B; n = 6 for C) treated
mice were incubated in RPMI medium for 24 h, released cytokines were
then determined by ELISA. We noted a marked difference in the gut
spontaneous secretion of TNF-a (B) in gut supernatants from VIVIT
treated mice, with a statistically significant change in IL-12 p40 (A) and
in interferon-c (C) production compared to VEET treated mice. Values
are normalized to weight of intestinal explants, and data are presented
as mean 6 SEM.
doi:10.1371/journal.pone.0034172.g008
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inhibitors regulated LPS-induced IL-12 p40 expression through a
mechanism that involved NF-kB [18].
In conclusion, these experiments demonstrate that NFAT plays
an important role in inflammatory gene expression in macro-
phages, and a specific short peptide inhibitor of NFAT
dephosphorylation, VIVIT, attenuates inflammation in a murine
model of experimental colitis. Cell permeable 11R-VIVIT peptide
could represent a novel therapeutic approach in chronic
inflammatory diseases where both innate and adaptive immune
responses play a role in pathogenesis.
Supporting Information
Figure S1 Inhibition of IL-12 p40 is not induced through
disruption of TLR4 signaling. BMDMs isolated from Il102/
2;NF-kBEGFP mice were exposed to 11R-VIVITEMD or 11R-
VEET for 1 hour prior to exposure to ultrapure LPS (100 ng/ml);
controls were exposed to LPS or PBS. Representative images of
high power field magnification 640 of GFP positive BMDMs
overlayed on total BMDMs. (A) PBS stimulated BMDMs. (B) LPS
stimulated BMDMs. (C) VEET and LPS stimulated BMDMs. (D)
VIVIT and LPS stimulated BMDMs. The experiment was
repeated on BMDM preparations from 3 different mice with
similar results.
(TIF)
Figure S2 Inflammation is attenuated following treat-
ment with 11R-VIVIT. (A) Representative photograph of
colons from VIVIT and VEET treated Il102/2 as indicated.
Colon from VIVIT treated mice show a clear decrease in tissue
thickening with well-formed stool pellets compared to those from
VEET treated mice. (B) Colons of piroxicam treated Il102/2 mice
were evaluated for pathology following two weeks of either VIVIT
or VEET injections. H&E stained colon tissue from VIVIT treated
mice show mild signs of inflammation and epithelial damage
compared to that from VEET treated mice. VIVIT treatment
protected piroxicam treated Il102/2 mice from epithelial
hyperplasia, crypt destruction, and inflammatory invasion in both
mucosa and sub-mucosa. Representative histological sections of
colons from treated and control mice are shown (magnification
610).
(TIF)
Figure S3 11R-VIVIT inhibits activated T cell cytokine
secretion. Levels of IFN-c were assessed as a measure of an
activated Th1 response in cells. Splenic CD4+ T cells from WT
mice were stimulated with plate bound anti-CD3 (5 mg/ml) and
anti-CD28 (2 mg/ml) (eBioscience) and exposed to various
concentrations of 11R-VIVITEMD or VEET. Cells were harvested
after 4 hours for mRNA and supernatants were collected after
48 hours for ELISA. IFN-c mRNA (A) and protein (B) were dose
dependently reduced by11R-VIVITEMD.
(TIF)
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